BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Y, Zhang Z, Hu Y, Yan X, Song Q, Wang G, Chen R, Jiao S, Wang J. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs). Front Oncol 2020;10:654. [PMID: 32656072 DOI: 10.3389/fonc.2020.00654] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Lenci E, Cantini L, Pecci F, Cognigni V, Agostinelli V, Mentrasti G, Lupi A, Ranallo N, Paoloni F, Rinaldi S, Nicolardi L, Caglio A, Aerts S, Cortellini A, Ficorella C, Chiari R, Di Maio M, Dingemans AC, Aerts JGJV, Berardi R. The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. J Clin Med 2021;10:1005. [PMID: 33801320 DOI: 10.3390/jcm10051005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Minichsdorfer C, Gleiss A, Aretin MB, Schmidinger M, Fuereder T. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy. Ann Med 2022;54:1339-49. [PMID: 35535695 DOI: 10.1080/07853890.2022.2070660] [Reference Citation Analysis]
3 Indini A, Rijavec E, Grossi F. Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review. Cancers (Basel) 2021;13:1794. [PMID: 33918661 DOI: 10.3390/cancers13081794] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Gao Y, Zhang Z, Li Y, Chen S, Lu J, Wu L, Ma Z, Hu Y, Zhang G. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy. Front Oncol 2022;12:834564. [PMID: 35494073 DOI: 10.3389/fonc.2022.834564] [Reference Citation Analysis]
5 Zeng H, Huang WW, Liu YJ, Huang Q, Zhao SM, Li YL, Tian PW, Li WM. Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer. Front Oncol 2021;11:685047. [PMID: 34458139 DOI: 10.3389/fonc.2021.685047] [Reference Citation Analysis]
6 Daniello L, Elshiaty M, Bozorgmehr F, Kuon J, Kazdal D, Schindler H, Shah R, Volckmar AL, Lusky F, Diekmann L, Liersch S, Faehling M, Muley T, Kriegsmann M, Benesova K, Stenzinger A, Thomas M, Christopoulos P. Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. Front Oncol 2021;11:703893. [PMID: 34268127 DOI: 10.3389/fonc.2021.703893] [Reference Citation Analysis]
7 Fatima S, Ma Y, Safrachi A, Haider S, Spring KJ, Vafaee F, Scott KF, Roberts TL, Becker TM, de Souza P. Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy. Cancers 2022;14:1669. [DOI: 10.3390/cancers14071669] [Reference Citation Analysis]
8 Chen J, Wei S, Zhao T, Zhang X, Wang Y, Zhang X, Mei J. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB. Disease Markers 2022;2022:1-25. [DOI: 10.1155/2022/7137357] [Reference Citation Analysis]
9 Stares M, Swan A, Cumming K, Ding TE, Leach J, Stratton C, Thomson F, Barrie C, MacLennan K, Campbell S, Evans T, Tufail A, Harrow S, MacKean M, Phillips I. Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer. Front Nutr 2021;8:734735. [PMID: 34660664 DOI: 10.3389/fnut.2021.734735] [Reference Citation Analysis]
10 Kim DW, Tan E, Zhou JM, Schell MJ, Martinez M, Yu J, Carballido E, Mehta R, Strosberg J, Imanirad I, Kim RD. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. Br J Cancer 2021;124:1803-8. [PMID: 33828254 DOI: 10.1038/s41416-021-01368-z] [Reference Citation Analysis]
11 Xiong A, Wang J, Zhou C. Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China. Front Oncol 2021;11:757993. [PMID: 34900707 DOI: 10.3389/fonc.2021.757993] [Reference Citation Analysis]
12 Guven DC, Aktepe OH, Aksun MS, Sahin TK, Kavgaci G, Ucgul E, Cakir IY, Yildirim HC, Guner G, Akin S, Kertmen N, Dizdar O, Aksoy S, Erman M, Yalcin S, Kilickap S. The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors. Cancer Biomark 2021. [PMID: 34958005 DOI: 10.3233/CBM-210349] [Reference Citation Analysis]
13 Guven DC, Sahin TK, Erul E, Cakir IY, Ucgul E, Yildirim HC, Aktepe OH, Erman M, Kilickap S, Aksoy S, Yalcin S. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy. JCM 2022;11:4523. [DOI: 10.3390/jcm11154523] [Reference Citation Analysis]
14 Peng LP, Li J, Li XF. Prognostic value of neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte ratios and Glasgow prognostic score in osteosarcoma: A meta-analysis. World J Clin Cases 2022; 10(7): 2194-2205 [DOI: 10.12998/wjcc.v10.i7.2194] [Reference Citation Analysis]
15 Liu H, Yang XL, Yang XY, Dong ZR, Chen ZQ, Hong JG, Li T. The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:691002. [PMID: 34631525 DOI: 10.3389/fonc.2021.691002] [Reference Citation Analysis]
16 Zhou J, Zhao J, Jia Q, Chu Q, Zhou F, Chu X, Zhao W, Ren S, Zhou C, Su C. Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer. Front Oncol 2021;11:625578. [PMID: 33816260 DOI: 10.3389/fonc.2021.625578] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Xuan J, Peng J, Wang S, Cai Y. Prognostic significance of Naples prognostic score in non-small-cell lung cancer patients with brain metastases. Future Oncol 2022. [PMID: 35107367 DOI: 10.2217/fon-2021-1530] [Reference Citation Analysis]
18 Niu M, Yi M, Li N, Luo S, Wu K. Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. Exp Hematol Oncol 2021;10:18. [PMID: 33653420 DOI: 10.1186/s40164-021-00211-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
19 Kauffmann-Guerrero D, Kahnert K, Kiefl R, Sellmer L, Walter J, Behr J, Tufman A. Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study. Sci Rep 2021;11:10919. [PMID: 34035415 DOI: 10.1038/s41598-021-90397-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Guven DC, Aktepe OH, Taban H, Aktas BY, Guner G, Yildirim HC, Sahin TK, Aksun MS, Dizdar O, Aksoy S, Erman M, Yalcin S, Kilickap S. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune checkpoint inhibitors. Biomark Med 2021;15:1123-30. [PMID: 34397271 DOI: 10.2217/bmm-2020-0674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Cho A, Kranawetter B, Untersteiner H, Khalaveh F, Dorfer C, Rössler K, Zöchbauer-Müller S, Gatterbauer B, Hochmair MJ, Frischer JM. Neutrophil-to-Lymphocyte Ratio Is Superior to Other Leukocyte-Based Ratios as a Prognostic Predictor in Non-Small Cell Lung Cancer Patients with Radiosurgically Treated Brain Metastases Under Immunotherapy or Targeted Therapy. World Neurosurg 2021;151:e324-31. [PMID: 33878466 DOI: 10.1016/j.wneu.2021.04.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Li L, Pi C, Yan X, Lu J, Yang X, Wang C, Li X, Zhang S, Zhang Z, Sun Y, Hu Y. Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy. Front Oncol 2021;11:697865. [PMID: 34692478 DOI: 10.3389/fonc.2021.697865] [Reference Citation Analysis]
23 Chen J, Wu X, Zhu S, Wang J. Changes in Neutrophil to Lymphocyte Ratio, Lymphocyte to Monocyte Ratio, and Platelet to Lymphocyte Ratio During Palliative Radiotherapy May Predict Efficacy of Immune Checkpoint Inhibitor as Re-Challenge Treatment in Advanced Gastric Cancer: A Case Report. Front Oncol 2022;12:873213. [PMID: 35664734 DOI: 10.3389/fonc.2022.873213] [Reference Citation Analysis]
24 Meng L, Xu J, Ye Y, Wang Y, Luo S, Gong X. The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients. Front Immunol 2021;12:723609. [PMID: 34621270 DOI: 10.3389/fimmu.2021.723609] [Reference Citation Analysis]
25 Liu N, Mao J, Tao P, Chi H, Jia W, Dong C. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. Medicine (Baltimore) 2022;101:e28617. [PMID: 35060536 DOI: 10.1097/MD.0000000000028617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Fujimoto A, Toyokawa G, Koutake Y, Kimura S, Kawamata Y, Fukuishi K, Yamazaki K, Takeo S. Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac Cancer 2021;12:2198-204. [PMID: 34173724 DOI: 10.1111/1759-7714.14063] [Cited by in F6Publishing: 1] [Reference Citation Analysis]